1. Home
  2. TVTX vs PII Comparison

TVTX vs PII Comparison

Compare TVTX & PII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$65.28

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Logo Polaris Inc.

PII

Polaris Inc.

HOLD

Current Price

$62.63

Market Cap

4.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
PII
Founded
N/A
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
4.2B
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
TVTX
PII
Price
$65.28
$62.63
Analyst Decision
Strong Buy
Hold
Analyst Count
13
11
Target Price
$40.62
$62.27
AVG Volume (30 Days)
1.2M
716.5K
Earning Date
05-04-2026
04-27-2026
Dividend Yield
N/A
4.05%
EPS Growth
92.89
N/A
EPS
N/A
N/A
Revenue
N/A
$7,152,000,000.00
Revenue This Year
$44.76
$1.20
Revenue Next Year
$35.51
$4.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.06
$47.14
52 Week High
$68.03
$77.98

Technical Indicators

Market Signals
Indicator
TVTX
PII
Relative Strength Index (RSI) 60.45 29.03
Support Level $53.76 $58.81
Resistance Level $66.24 $70.62
Average True Range (ATR) 1.98 2.14
MACD -0.14 -0.55
Stochastic Oscillator 71.85 2.70

Price Performance

Historical Comparison
TVTX
PII

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About PII Polaris Inc.

Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.

Share on Social Networks: